Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ ASX Shares
Buy and hold Cochlear and these ASX shares for strong long term returns
Healthcare Shares
Why Mesoblast might be the best ASX healthcare growth share to own right now
Capital Raising
What you need to know about Downer's share price, $400m cap raise and acquisition
Share Market News
Top brokers name 3 ASX shares to sell next week
Share Market News
3 ASX medical shares to hold for the long term
Share Market News
2 quality ASX healthcare shares to snap up at more attractive prices
⏸️ Investing
2 ASX shares that could be 10-baggers
Healthcare Shares
Why I think the Polynovo share price is a buy right now
Share Market News
Top brokers name 3 ASX 200 shares to sell next week
⏸️ ASX Shares
3 of the best ASX 50 shares to buy right now
Share Market News
Top brokers name 3 ASX shares to buy right now
⏸️ ASX Shares
Where to invest $20,000 into ASX shares for market-beating returns
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
